USV Expands Diabetes Portfolio with Cost-Effective Liralin-EP in India
USV Pvt. Ltd., launches the Liralin EP a combination of Linagliptin & Empagliflozin at just Rs 12.90 per tablet for strengthening it's affordable diabetes care range. Liralin EP contains the world's 1st approved DPP4i + SGLT2i combination for the management.
It is available in two strengths to cater to varied patient needs- Liralin-EP 10 contains Empagliflozin 10 mg and Linagliptin 5 mg, while Liralin-EP 25 contains Empagliflozin 25 mg and Linagliptin 5 mg.
Given the loss of patency of Empagliflozin in India, USV has priced the drug at very affordable levels for the convenience of patients. Liralin-EP 10 at ₹12.90 per tablet and Liralin-EP 25 at ₹13.90 per tablet, making quality diabetes management accessible to a wider patient population across India.
Liralin-EP combines Linagliptin, a DPP-4 inhibitor, with Empagliflozin, an SGLT2 inhibitor, offering complementary mechanisms to effectively lower blood glucose levels while providing added cardiovascular and renal benefits.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.